'Data-Rich' Sources Can ID Niaspan Class, 3rd Circ. Told

By Bryan Koenig (January 21, 2022, 5:57 PM EST) -- Antitrust advocacy groups want the Third Circuit to reverse a Pennsylvania federal judge's decision refusing to certify a class of end-payors alleging improper pay-for-delay settlements between AbbVie and Teva Pharmaceuticals delaying generic forms of cholesterol drug Niaspan, arguing there's ample data to identify class members.

The American Antitrust Institute and the Committee to Support the Antitrust Laws filed separate amicus briefs urging the reversal of U.S. District Judge Jan DuBois' August determination that the health plans and others comprising the end-payors failed to put forward a reliable and feasible plan for distinguishing between proposed class members and intermediaries in drug transactions...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!